| Achillion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. Co.'s focus is on its complement inhibitor platform, directed at developing small molecule compounds to be used in the treatment of immune-related diseases. The alternative pathway plays a role in a number of disease conditions including rare orphan conditions such as paroxysmal nocturnal hemoglobinuria, a blood disorder, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, both kidney diseases, as well as several more prevalent indications. The ACHN YTD return is shown above.
The YTD Return on the ACHN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ACHN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACHN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.